Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung CancerElena V. Ivanova, Pasi A. Jänne, Mari Kuraguchi et al.|Clinical Cancer Research|2020Cited by 42
Figure S3 from Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung CancerElena P. Ivanova, Pasi A. Jänne, Shengwu Liu et al.|Unknown|2023Cited by 0
Supplemental Legend from Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung CancerElena P. Ivanova, Pasi A. Jänne, Mari Kuraguchi et al.|Unknown|2023Cited by 0
Supplementary Table S1 from Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung CancerElena P. Ivanova, Pasi A. Jänne, Mari Kuraguchi et al.|Unknown|2023Cited by 0
Figure S4 from Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung CancerElena P. Ivanova, Pasi A. Jänne, Mari Kuraguchi et al.|Unknown|2023Cited by 0